|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003250,
umls-concept:C0007137,
umls-concept:C0013216,
umls-concept:C0030705,
umls-concept:C0034897,
umls-concept:C0036525,
umls-concept:C0205195,
umls-concept:C0205390,
umls-concept:C0206454,
umls-concept:C0460004,
umls-concept:C0995188,
umls-concept:C1096776,
umls-concept:C1514162,
umls-concept:C1522484
|
|
pubmed:issue |
24
|
|
pubmed:dateCreated |
2005-8-19
|
|
pubmed:abstractText |
To evaluate the efficacy and safety of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
20
|
|
pubmed:volume |
23
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
5568-77
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16009950-Adult,
pubmed-meshheading:16009950-Aged,
pubmed-meshheading:16009950-Aged, 80 and over,
pubmed-meshheading:16009950-Antibodies, Monoclonal,
pubmed-meshheading:16009950-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16009950-Carboplatin,
pubmed-meshheading:16009950-Carcinoma, Squamous Cell,
pubmed-meshheading:16009950-Cisplatin,
pubmed-meshheading:16009950-Disease Progression,
pubmed-meshheading:16009950-Dose-Response Relationship, Drug,
pubmed-meshheading:16009950-Drug Administration Schedule,
pubmed-meshheading:16009950-Female,
pubmed-meshheading:16009950-Head and Neck Neoplasms,
pubmed-meshheading:16009950-Humans,
pubmed-meshheading:16009950-Infusions, Intravenous,
pubmed-meshheading:16009950-Male,
pubmed-meshheading:16009950-Maximum Tolerated Dose,
pubmed-meshheading:16009950-Middle Aged,
pubmed-meshheading:16009950-Neoplasm Recurrence, Local,
pubmed-meshheading:16009950-Quality of Life,
pubmed-meshheading:16009950-Survival Analysis,
pubmed-meshheading:16009950-Treatment Outcome
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck.
|
|
pubmed:affiliation |
Vall d'Hebron University Hospital, Oncology Service, P Vall d'Hebron 119-129, Barcelona 08035, Spain. jbaselga@vhebron.net
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
